Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male 18 years or older~* Histopathologically-proven PCa~* Unfavorable IR to HR disease:~  * Prostate specific antigen (PSA) \>= 10 ng/mL~ * Or cT-stage \>= 2b~ * Or Gleason grade 3 (4+3=7) or higher~ * Or Gleason grade 2 (3+4=7) AND \>= 50% positive biopsy cores~ * Or Decipher Score \>= 0.45~* Treating radiation oncologist intends to incorporate PSMA PET findings into the radiotherapy plan, if patient undergoes PSMA PET (intervention arm 2)~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~Exclusion Criteria:~* Less than 18 years old at the time of investigational product administration~* Extra-pelvic metastasis (M1 disease) on any imaging or biopsy done before randomization~* Prior PSMA PET~* Prior pelvic RT~* Contraindications to radiotherapy (including active inflammatory bowel disease)~* Concurrent or prior surgery or systemic therapy for PCa at the time of randomization

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (dRT) (Type: ACTIVE_COMPARATOR): 150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
- Arm II (18F-DCFPyL, PET/CT, dRT) (Type: EXPERIMENTAL): 162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.

Based on this trial design, predict the completion outcome and termination type (if applicable).